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Abstract Relaxins are known for their tissue remodeling
capacity which is also a hallmark of cancer progression.
However, their role in the latter context is still unclear,
particularly in breast cancer. In a mouse model with
spontaneously arising breast cancer due to erbB2-overex-
pression we show that exposure to porcine relaxin results in
significantly enhanced tumour growth as compared to
control animals. This is accompanied by increased serum
concentrations of progesterone and estradiol as well as
elevated expression of the respective receptors and the
relaxin receptor RXFP1 in the tumour tissue. It is also
associated with enhanced infiltration by tumour-associated
macrophages which are known to promote tumour pro-
gression. Additionally, we show in an ex vivo model of
metastatic brain colonization that porcine relaxin as well as
human brain-specific relaxin-3 promotes invasion into the
brain tissue and enhance interaction of breast cancer cells
with the resident brain macrophages, the microglia.
Relaxin signaling is mediated via RXFP1, since R 3/I5, a
specific agonist of the relaxin-3 receptor RXFP3 in the
brain, does not significantly enhance invasion. Taken
together, these findings strongly support a role of relaxins
in the progression of breast cancer where they foster pri-
mary tumour growth as well as metastatic colonization by
direct and indirect means.
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Introduction
The mammalian peptide hormone relaxin and its human
analogue H2 relaxin or relaxin-2 are well known for their
matrix-modifying capacity. They induce extensive tissue
remodeling via upregulation of matrix metalloproteinases
(MMP) and angiogenesis [1, 2]. Since this is also a key
feature of malignant invasion, they have been implicated in
cancer progression. However, their role in this context is
still unclear.
The most unambiguous data exist for prostate cancer. In
xenografts of relaxin-2-overexpressing prostate cancer cell
lines, tumour growth and neoangiogenesis are significantly
enhanced [3]. The opposite can be observed after trans-
fection of an antagonistic relaxin-2 analogue lacking the
binding domain for the relaxin receptor RXFP1 [4].
Increased production of relaxin-2 as well as relaxin by
tumour and stromal cells has been demonstrated in
advanced prostate cancers in humans and mice [5, 6].
Relaxin enhances proliferation, adhesion and invasion
in vitro as well as tumour growth in the TRAMP mouse
Electronic supplementary material The online version of this
article (doi:10.1007/s10585-013-9609-2) contains supplementary
material, which is available to authorized users.
C. Binder (&)  E. Chuang  A. Bleckmann  M. Schulz
Department of Haematology/Oncology, Georg-August-
University, Robert-Koch-str. 40, 37075 Go¨ttingen, Germany
e-mail: cbinder@med.uni-goettingen.de
C. Habla  A. Einspanier (&)
Institute of Veterinary Physiological Chemistry, University of
Leipzig, An den Tierkliniken 1, 04103 Leipzig, Germany
e-mail: einspanier@vetmed.uni-leipzig.de
A. Bleckmann
Deparment of Medical Statistics, Georg-August-University,
Go¨ttingen, Germany
R. Bathgate
Florey Neuroscience Institutes and Department of Biochemistry
and Molecular Biology, University of Melbourne, Parkville,
VIC, Australia
123
Clin Exp Metastasis (2014) 31:57–65
DOI 10.1007/s10585-013-9609-2
model in vivo, while deficiency of RXFP1 antagonizes this
effect [5, 7]. A tumour-promoting function of relaxin-2 has
been demonstrated also in thyroid cancer where it fosters
invasion in vitro via increased invadopodia formation and
MMP upregulation as well as xenograft growth in nude
mice [8, 9]. Relaxin-2 expression was also enhanced in
advanced human endometrium cancers correlating with
unfavourable clinical outcome [10].
In breast cancer, the situation is much less clear. Ele-
vated expression of relaxin-2 has been demonstrated in
neoplastic mammary tissues as compared to their benign
counterparts [11]. Porcine relaxin as well as relaxin-2 was
found to influence tumour cell proliferation in a biphasic
way regarding time course and concentration. While low
amounts and short-term application resulted in enhanced
in vitro growth of MCF-7 and MDA MB-231 cells, high
concentrations and long-term exposure yielded the oppo-
site effect and diminished the growth of the respective
xenografts in nude mice [12–14]. We showed that 5-day
exposure of MCF-7 and SK-BR3 cells to 100 ng/ml of
porcine relaxin as well as recombinant relaxin-2 was fol-
lowed by MMP upregulation and enhanced invasiveness.
This could be inhibited by the antagonistic relaxin-2 ana-
logue B-R13/17 K [15, 16]. Consistently, relaxin-2 serum
levels were significantly elevated in patients with meta-
static breast cancer correlating with short survival [17].
To further complicate matters, relaxins do not only act
on the tumour cells but also on the benign cells of the
surrounding stromal compartment. Components of the
tumour microenvironment are essentially involved in
malignant progression, in particular, the tumour-associated
macrophages (TAM) which are characterized by a so-
called M2 phenotype with tumour-promoting function [18].
We have recently shown that not only the TAM, infiltrating
from the peripheral blood, but also resident macrophages at
the site of metastasis are critical for the colonization of
distant organs [19, 20]. Interestingly, Figueiredo et al. [21]
have shown that relaxin inhibits expression of the typical
M1-cytokine IL 1b in rat macrophages, thus indicating a
potential role for relaxins in the tumour-associated phe-
notype shift to M2.
Given the impact of microenvironment effects on
tumour growth we searched for a model where the influ-
ence of relaxins on breast cancer progression could be
studied without confounding factors, such as xenografting,
artificial cancer induction/injection or immunodeficiency.
We therefore chose the Tg(MMTV-erbB2) mouse model,
where breast cancers arise spontaneously due to transgenic
erbB2-overexpression [22]. Since erbB2-overexpressing
tumours are clinically aggressive and often metastasize into
the brain [23], we additionally used the organotypic brain
slice coculture, an ex vivo model recently established by
our group [19], to study the effect of porcine relaxin as well
as the human brain isoform relaxin-3 on the colonization of
the central nervous system.
Materials and methods
Animals and experimental design
Animal experiments were approved by the local committee
of Animal Care and Use (nr. 509.42502/01-37.01).
Tg(MMTV-erbB2) mice (Charles River, Sulzfeld, Ger-
many) were housed and bred under standard conditions.
Hemizygous female mice develop spontaneous cancers in
almost all mammary glands within 4–6 months after birth
due to overexpression of the rat erbB2-transgene driven by
the MMTV-promotor [22]. Presence of the transgene was
confirmed by DNA analysis in 45 female mice, which were
then divided into a control (n = 23) and a relaxin group
(n = 22). From day 100 on after birth animals were
monitored closely by daily inspection and palpation.
Osmotic pumps (nr. 2004, Alzet, Cupertino/Canada), filled
either with porcine relaxin (6.5 ng/ml; 0.28 ll/h) or 0.9 %
sodium chloride, were implanted into the neck area at the
first sign of mammary gland tumour development (d 1 of
the study period). After euthanasia, mammary glands were
examined for tumour development. Tumours were mea-
sured and weighed before fixation in liquid nitrogen and
paraformaldehyde. Internal organs were inspected for
metastasis and were collected for histological evaluation.
Determination of serum relaxin, estradiol
and progesterone
Serum relaxin concentrations were determined using an
enzyme immunoassay which had been validated for por-
cine and human relaxin as described previously [24]. Since
our aim was primarily to detect porcine relaxin in order to
confirm the correct delivery via the pumps, this assay was
suitable. The lower detection limit was 0.07 ng/ml. It has
been shown earlier that the antibody used for this assay
also detects murine relaxin. To confirm this, we performed
measurements in six pregnant mice (day 17) yielding val-
ues corresponding to the literature for this stage of preg-
nancy. Upon serial dilution, the curve was parallel to our
porcine standard curve. As to be expected, relaxin was
undetectable in 6 male mice. Serum estrogen (E2) levels
were examined using a commercial ELISA kit (IBL
International GmbH, Hamburg, Germany) according to the
manufacturer’s instructions. Serum progesterone (P4) was
measured via enzyme immunoassay as described previ-
ously [24]. The lower detection limits were 0.016 ng/ml for
E2 and 0.06 ng/ml for P4, respectively.
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Histology and immunohistochemistry
Organs were embedded in paraffin, cut (5 lm sections,
microtome HM 36, Microm, Walldorf, Germany) and
mounted on 0.01 % poly-L-lysine coated glass slides
(Sigma, Deisenhofen, Germany). Hematoxylin-eosin
staining (HE; Merck, Darmstadt, Germany) was performed
for morphological overview. For immunohistochemical
analysis, the following primary antibodies were used:
monoclonal rabbit anti estrogen receptor (ER) a (Eurom-
edex, Souffel Weyersheim, France, 1:1,000), rabbit anti
progesterone receptor (PR) (Immunotech, Krefeld, Ger-
many, 1:4,000), polyclonal rabbit anti porcine relaxin
(serum 258, courtesy of OD Sherwood, Illinois, US),
mouse anti human clone MAC 387 (Dako, Hamburg,
Germany, 1:600) for the histiocyte antigen MAC 387;
polyclonal rabbit anti mouse Ki67 (1:400, courtesy of
Dr. Scholzen, Ju¨lich, Germany) and polyclonal rabbit anti
human RXFP1 (1:2,000, courtesy of Richard Ivell, Dum-
merstorf, Germany). The validation protocol for the
RXFP1 antibody has been described in [25]. To ensure that
it also recognizes the murine receptor we additionally
validated the antibody in mouse uterine and heart tissue.
This yielded the same results as to be expected from the
literature. After deparaffinization, pre-treatment with cit-
rate solution (pH 6, 40 min at 90 C) and a trypsin diges-
tion step (15 min), slides were incubated with 3 % H2O2
(20 min) for inhibition of endogenous peroxidases. The
primary antibodies were applied at 4 C overnight. Stain
was developed using horseradish peroxidase-coupled goat
anti-mouse/anti-rabbit secondary antibodies (DAKO
EnVision detection kit, Dako Cytomation, Hamburg, Ger-
many) and the Vector AEC substrate kit as a chromogen
(Linaris, Germany). Mouse-anti-rabbit-IgG (Dianova,
Hamburg, Germany) was used as negative control.
Microscopical evaluation was performed independently by
two different persons counting 100 cells per sample and
classifying them as positive or negative.
RT-PCR
Total RNA was extracted with the guanidinium thiocyanate
method [26] followed by reverse transcription using oligo-
dT primers (Invitrogen GmbH, Karlsruhe, Germany). The
murine RXFP1 transcript as well as human RXFP1,2 and 3
were analyzed by semi-quantitative RT-PCR using ribo-
somal 18 and 26S as controls. Primers were designed using
the NCBI Primer-BLAST (http://ncbi.nlm.nih.gov/tools/
primer-blast/index.cgi) based on the published sequence
[27, 28]. RT-PCR was performed on the RotorGene 6000
(Corbett Lifescience, Qiagen, Hilden, Germany) with the
29 SensiMix dt Kit (Quantace Ltd, London, UK) accord-
ing to the instructions of the manufacturer. Each sample
was analyzed in duplicate and in two separate runs. The
PCR cycle conditions for the primers were as follows:
10 min at 95 C, 45 cycles of 30 s at 54–58 C, 15 s at
72 C with a final melting curve analysis to confirm the
specifity of the amplified products. PCR products were
analysed by gel electrophoresis.
Organotypic brain slice coculture model
Slice cocultures were performed as described previously
[19]. Briefly, NMRI mice (p5–p7) were decapitated, and
brains were removed under aseptic conditions. Horizontal
whole brain sections (400 lm, vibratome Leica VT1000S;
Leica, Wetzlar, Germany) were transferred onto a 0.4 lm
polycarbonate membrane in a transwell tissue insert (Fal-
con, model 3090, Becton–Dickinson) and incubated within
a 6-well dish in 50 % MEM, 25 % Hanks’ balanced salt
solution (Gibco, Karlsruhe, Germany), 25 % normal horse
serum, 0.2 mM glutamine, 100 U/ml penicillin, 100 mg/ml
streptomycin and 4.5 mg/ml glucose. After 24 h, 105
tumour cells, embedded in 20 ll RPMI with 85 % extra-
cellular matrix gel (R&D Systems, Wiesbaden, Germany)
were placed next to the intact outside of the slice. The
breast cancer cell lines used for these experiments were
either transfected with a GFP-expression vector or stained
with the fluorescent membrane dye PKH67 (Sigma-
Aldrich, Steinheim, Germany). Porcine relaxin, synthetic
human relaxin-3 and the RXFP3-agonist R3/I5 were added
to the medium at the indicated concentrations. After 72 h,
brain slices and tumour plug were fixated in 4 % parafor-
maldehyde, removed together from the inserts and washed
with PBS/0.2 % Triton-X-100. Slices and adherent tumour
plugs were then stained with fluorescence dye-conjugated
Griffonia simplicifolia isolectin B4 (1:100, Alexa Fluor
568- ILB4; Invitrogen, Karlsruhe, Germany), mounted in
DAKO fluorescent mounting medium (S-3023, DakoCy-
tomation, Glostrup, Denmark) and analyzed using a con-
focal laser scanning microscope (LSM 510, Zeiss,
Go¨ttingen, Germany).
Statistics
Statistical analysis was carried out using the SPSS15
software (SPSS, Munich, Germany) and the free statistical
software R (version 2.13.1; http://www.r-project.org). The
influence of volume, day and treatment was investigated by
using a multivariate linear regression model for both end-
points volume and weight. In order to assess the influence
of the treatment, the slope of the regression lines of the two
groups were compared. Parametric data were analysed with
the two-sided Student’s t test. A p value \0.05 was con-
sidered significant.
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Results
Relaxin enhances local tumour growth
The first palpable tumours developed between days 130
and 185 after birth predominantly in the caudal mammary
glands with progression to almost all glands later on. After
implantation of the osmotic pumps (day 1 of the experi-
mental period), containing either porcine relaxin or sodium
chloride, animals were monitored clinically and sacrificed
out of ethical considerations in any case where tumour
progression affected their well-being. Some of them were
killed also at earlier time points after pump implantation to
allow continuous assessment of tumour growth.
The median time to euthanasia was shorter in the relaxin
group (Table 1). None of these animals could be left alive
after day 29 of the experimental phase, in contrast to the
control group where some animals lived until day 36.
However, due to the elective early euthanasias the differ-
ence did not reach statistical significance. Evaluation of the
total tumour volume per mouse confirmed that relaxin-
treated mice developed larger tumours at earlier time
points. The median total tumour volume was higher in
relaxin-treated animals (Table 1). This was strongly sig-
nificant considering the first 29 days where animals from
both groups were still alive. Large tumours were found also
in control animals, but only later on. Statistical analysis of
the volume–time correlation using a multivariate linear
model further corroborated these findings and yielded a
significant difference in local tumour progression with
faster growth in the relaxin-treated group (Fig. 1). The
mean absolute body weight at euthanasia did not differ sig-
nificantly (? relaxin: 29 ± 2.1 g; controls: 30.6 ± 3.1 g;
p = 0.11). There were no detectable metastases in any of the
animals, neither macroscopically nor after histological
evaluation of the potential target organs including the brain.
To confirm correct relaxin delivery, relaxin serum levels
were determined at euthanasia (Table 2). As expected, we
found significantly higher peripheral relaxin concentrations
in the relaxin group than in the control animals. Moreover,
serum estradiol (E2) and progesterone (P4) levels were also
significantly increased in the relaxin group, thus, indicating
an influence of relaxin on production of these hormones.
Relaxin induces proliferation and facilitates
macrophage invasion
Upon morphological examination of the H&E-stained
samples, tumours in relaxin-treated and control animals did
not differ from each other. There was no fibrous capsule
around the tumours in either of the groups. However, there
was a significant increase in the proliferation rate of
tumours from relaxin-treated animals as shown by Ki67-
staining (Table 3; Fig. 2). Expression of the ER was
moderate with considerable interindividual variations in
both groups, however, it was significantly lower in the
control group. PR expression was generally low, but also
significantly lower in the control tumours. Equally, RXFP1
Table 1 Day of euthanasia (after pump implantation) and tumour volume
? Relaxin Controls p value
Median 25–75 % quartiles Min–max Median 25–75 % quartiles Min–max
Total tumour volume (cm3)
Days 1–29 10.1 4.7–11.4 2.1–21.8 2.6 1.7–4.2 1.1–7.5 0.0005
Days 1–36 10.1 4.7–11.4 2.1–21.8 3.9 2.2–10.4 1.1–20.7 [0.05
Day of euthanasia 24 23–26 15–28 27.5 18.5–32 14–36 [0.05
Fig. 1 Porcine relaxin fosters local tumour growth in the Tg(MMTV-
erbB2) mouse. Graphical presentation of the multivariate linear model
of the volume–time correlation, showing earlier development of large
tumours in animals treated with porcine relaxin than in controls
(p = 0.033; dashed line linear regression curve relaxin group, solid
line controls)
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was less frequently expressed in control tumours than in
tumours from relaxin-treated mice (p \ 0.01). Since mac-
rophages are responsive to relaxin [21], we measured the
amount of TAM in the various tumour samples. In fact,
there was a significantly higher degree of TAM infiltration
in the relaxin-exposed tumours than in the controls. TAM
were not only localized in the stromal compartment as
presented in Fig. 2, but also within the malignant tissues.
The tumours also expressed relaxin, ranging from focal up
to diffuse positivity, however, without any difference
between control and relaxin group (suppl. Figure 1).
Relaxins enhance malignant colonization of brain tissue
In humans, erbB2-positive tumours tend to metastasize
early and often disseminate into the brain. However, we
were not able to detect any metastases. The animals had to
be euthanized when the local tumours became too large, a
time span which may have been too short to allow meta-
static dissemination. To further address this question, we
used a murine ex vivo model of brain colonization, recently
established by our group [19]. There, invasion of tumour
cells into the living brain tissue can be followed over
several days. Additionally, the system allows observation
of the reaction of stromal components, in particular the
microglia, the resident macrophages of the brain.
To mirror the conditions in the animal model and to
achieve a purely murine setting, we first used the mouse
breast cancer cell line 4T1. As shown in Fig. 3a, porcine
relaxin significantly enhanced invasion of the tumour cells
into the brain slice. The same could be shown for the
human erbB2-positive breast cancer cell line SK-BR3 as
well as for the erbB2-negative and hormone receptor-
positive cell line MCF-7. In this model, we have previously
demonstrated that successful tumour cell invasion requires
interaction with microglia which are attracted, activated
and subsequently mediate the transport of the malignant
cells into the brain tissue [19]. Addition of relaxin clearly
enhanced this reaction and lead to increased accumulation
of microglia at the site of tumour cell entry.
Next, we were interested in whether the brain-specific
relaxin-3 would achieve the same effect. The genuine
receptor for relaxin-3 is RXFP3, expressed predominantly
in brain tissue, in particular in the basal regions [29] where
the whole brain slices are cut from. Relaxin-3 can addi-
tionally bind to RXFP1, also present in the brain. In the
tumour cells, we could detect only RXFP1 and 2, RXFP3
was absent (Fig. 3b–d, not shown for 4T1). Invasion of
MCF-7 cells as well as microglia accumulation was sig-
nificantly increased by synthetic human relaxin-3 in a
concentration-dependent way (Fig. 3e–h). We then asked
whether relaxin-3 exerts its effect via its specific receptor
RXFP3 or via RXFP1 in both tumour cells and brain. In
contrast to relaxin-3, the specific RXFP3 agonist R3/I5 was
only weakly pro-invasive (Fig. 3h), suggesting that relaxin-
3 enhances invasion predominantly via RXFP1.
Discussion
While there is increasing evidence of a tumour-promoting
role of relaxins in prostate and several other cancers, the
data for breast cancer are still contradictory. Here we show
that porcine relaxin significantly enhances growth of breast
cancers which had developed spontaneously in an erbB2-
overexpressing mouse model. This was associated with a
significantly higher proliferation rate in tumours from
relaxin-treated animals as well as with upregulation of
RXFP1 expression. Additionally, relaxin-treated animals
had significantly higher serum levels of E2 and P4, which
was accompanied by increased expression of the respective
receptors in the tumours. Induction of RXFP1 either
directly by its ligand or indirectly via E2 which, in turn,
can be upregulated by relaxin [30]), has already been
demonstrated in the marmoset monkey [30] and in the pig
[31]. In the mouse cervix, activation of ERa-signaling was
Table 2 Hormone serum
concentrations at euthanasia
(mean ± SD)
? Relaxin Controls p value
Relaxin (ng/ml) 0.71 ± 0.38 0.108 ± 0.109 0.000001
P4 (ng/ml) 0.79 ± 0.37 0.28 ± 0.22 0.000031
E2 (ng/ml) 0.23 ± 0.12 0.13 ± 0.52 0.0056
Table 3 Histological tumour
characteristics (mean ± SD)
? Relaxin Controls p value
Ki67? (%) 40.4 ± 11.05 8.18 ± 5.8 0.00000003
ER? (%) 33.73 ± 11.05 15.90 ± 6.04 0.000064
PR? (%) 6.2 ± 3.10 1.92 ± 1.16 0.00018
RXFP1? (%) 39.2 ± 14.14 9.09 ± 5.2 0.00001
MAC 387? (%) 38.8 ± 11.76 9.45 ± 4.27 0.0000005
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necessary to enable the proliferative effect of relaxin [32].
This suggests that in our model relaxin stimulates tumour
growth by one or both of the following options: either
directly via upregulation of its own receptor or indirectly
via induction of sex hormones which then enhance prolif-
eration through their corresponding receptors.
As an indication that relaxin did not only act on tumour
but also on stromal cells, we found significantly elevated
amounts of infiltrating TAM in tumours from relaxin-
treated animals. Although the TAM were localized pre-
dominantly in the stromal compartment, they also infil-
trated into the tumour tissue itself. This demonstrates that
interaction between tumour and stroma in this spontaneous
model could occur freely without interference of local
obstacles, such as formation of a surrounding fibrous cap-
sule, or of species barriers as often the case in artificially
induced cancers in both immunocompetent and deficient
mice [5, 12, 13]. Since high amounts of TAM are well-
known to confer an unfavourable clinical outcome [33],
relaxin-induced TAM infiltration may have additionally
contributed to enhanced tumour growth.
These data are consistent with our earlier findings that
both porcine relaxin and human relaxin-2 enhance breast
cancer cell invasion [15, 16]. In vivo, we could show that
elevated relaxin-2 serum levels in breast cancer patients
correlate with metastatic disease [17] and high RXFP1
mRNA levels are an independent marker of metastasis and
shortened survival in dogs [34]. In contrast to these results,
other authors described reduced growth of relaxin-2-over-
expressing MDA-MB 231 cells [13] as well as a differen-
tiating effect of relaxin on MCF-7 cells in nude mice [12].
Both groups used xenograft models in immunodeficient
animals with all the potential problems regarding the
microenvironment interaction mentioned above. Addition-
ally, the MDA-MB 231 transfectants produced up to
50-fold enhanced local relaxin-2 concentrations [13]. This
is clearly higher than in our model where systemic relaxin
levels were around 10-10 M and only about fivefold higher
in relaxin-treated animals than in controls. The amount of
relaxin is an important variable, since Sacchi et al. [14]
have shown that MCF-7 cells respond to higher versus
lower relaxin concentrations with opposite functional
outcome, levels of \8 9 10-10 M inducing tumour cell
proliferation.
The biphasic concentration effect may also explain the
divergent data of another group [35, 36] which generated
high intratumoural concentrations of relaxin either by
direct overexpression of relaxin in the injected breast
cancer cells or by delivery via infiltrating monocytic cells
with artificial relaxin overexpression. Although there was
excessive matrix remodeling around the tumours which
usually is a hallmark of cancer progression, the tumours
grew slower than the controls. This surprising effect was
attributed to facilitated accessibility for lymphocytes and
macrophages with antitumour activity. Supposedly, local
relaxin levels were rather high in this model, RLN1 mRNA
expression being described as more than fivefold increased
in the monocyte approach and 50–180 fold in the trans-













Fig. 2 Porcine relaxin influences histological tumour characteristics.
a Immunohistochemical assessment of proliferation (Ki67), macrophage
infiltration (MAC 387), expression of hormone receptors and RXFP1,
showing enhanced positivity for all parameters in the relaxin group. IgG
negative controls are shown in inserts. Scale bars 50 lm, magnifica-
tion 940 (except Ki 67: 920). b Expression of RXFP1 mRNA (RT-
PCR) in tumours from relaxin-treated animals (lane 2–5, 7, 9–11) but not
in control animals (lane 1, 6, 8, 12–15; lane 16 neg. control)
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Fig. 3 Relaxins enhance brain colonization in whole brain organo-
typic slice cocultures. a Quantification of cancer cell invasion in
murine brain slices. The histogram of the different degrees of invasion
(for details see ‘‘Materials and methods’’ section) shows enhanced
colonization by human and murine breast cancer cells upon incuba-
tion with porcine relaxin. *p = 0.012, **p = 0.042, ***p = 0.026,
each versus the respective controls. b RXFP expression in MCF-7
cells (RT-PCR): lane 1 RXFP1 (297 bp), lane 2 RXFP2 (302 bp),
lane 3 RXFP3 (189 bp), lane 4 loading control 26S (326 bp), lane 5
neg. control. c RXFP1 protein in MCF-7 cells (Western blot).
d RXFPs in SK-BR3 cells (RT-PCR): lane 1 RXFP1, lane 2 RXFP2,
lane RXFP3. e–g Confocal microscopy of whole brain organotypic
slice cocultures: green GFP-transfected MCF-7 cells; red microglia
stained with isolectin IB4. Tumour cells on the left side, embedded in
ECM (showing some unspecific diffuse red staining), invade into the
brain slice (right side, slice border dashed line) and colocalize with
red microglial cells. e Control, showing only few invading cells and
no microglial reaction after 72 h. f The RXFP3 agonist R3/I5 (2 lg/
ml) does not significantly enhance invasion. g Pronounced invasion
and microglia accumulation upon addition of relaxin-3 (2 lg/ml).
h Quantification of MCF-7 invasion in the whole brain organotypic
slice cocultures presented in e–g. *p = 0.011 versus control,
**p = 0.013 versus control. (Color figure online)
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have been described to induce a cytotoxic TH1-shift in
CD4 ? T cells [37], this would in fact support the concept
of a T-cell induced antitumour response in this model.
However, in vivo tumour-infiltrating T-cells and macro-
phages usually display a tumour-promoting TH2 and M2
phenotype. Figueiredo et al. [21] have shown that con-
centrations of relaxin-2 as low as 0.02 ng/ml shift the
macrophage phenotype from M1 to M2. Consistently, in
our model with relatively low relaxin levels, enhanced
infiltration by TAM upon relaxin treatment was not asso-
ciated with inhibition of tumour growth but with the
opposite.
Until now the influence of relaxins on spontaneous
metastasis formation is unclear. Since we could not detect
any metastases during the life span of our mice, we
addressed this question in a brain slice coculture model
[19]. There we had shown before that tumour cells need the
active help of microglia, the resident macrophages of the
brain, for successful invasion. First, microglia is attracted
and accumulates at the site of the potential tumour cell
entry. Activated microglia then serve as vehicles and
guidance structures for the malignant cells into the brain.
Porcine relaxin increased microglia accumulation and
invasion of each of the tumour cell lines investigated in this
model, independent of the species of origin as well as of
erbB2 and hormone receptor expression. The effect was
dose-dependent and became most significant in higher
concentrations. These concentrations are higher than those
used in our previous Boyden chamber experiments [15],
however, since relaxin is distributed via diffusion within
the brain slice, they are necessary to ensure sufficient
penetration. To further characterize the receptors which
mediate the pro-invasive effect, we applied the brain-spe-
cific relaxin-3 which binds with high affinity to its primary
receptor RXFP3 but can also interact with lower affinity
with RXFP1. Both receptors were present in the brain, but
only RXFP1 was expressed on the tumour cells. Synthetic
human relaxin-3 induced a similar pro-invasive effect as
porcine relaxin. In comparison, the specific RXFP3-agonist
R3/I5 did not significantly enhance invasion. Thus, it can
be assumed that most of the pro-invasive effect is mediated
by RXFP1 both on tumour cells and their stromal recipi-
ents, the microglia.
These results are consistent with a recent clinical
observation in a patient with hormone receptor-negative
breast cancer [38]. There, we found an unusually fulminant
progression from a single small osteolytic lesion to widely
disseminated metastases in multiple organs during hor-
monal treatment for oocyte harvest before the planned
chemotherapy. This was associated with induction of high
relaxin-2 serum levels, strongly suggesting a tumour-pro-
moting effect of relaxin-2 either directly on the tumour
cells or via the microenvironment.
Taken together, in a mouse model of spontaneous
erbB2-positive breast cancer, where interactions between
tumour cells and the stromal compartment are not ham-
pered by species barriers and immunodeficiency, relaxins
clearly promote tumour progression. This is obviously due
to effects of relaxins on the tumour cells but also on the
microenvironment, in particular, the macrophages. We also
demonstrate that relaxins can foster metastatic colonization
of the brain, again, via direct action on the tumour cells but
also on the recipient tissue. These findings strongly argue
in favour of a tumour-promoting role for relaxins in breast
cancer. Given the context-dependency of relaxin action,
further experiments with special attention to an intact
microenvironment and to relaxin dosage are warranted.
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